Lukasz Kuzma/LinkedIn
Feb 16, 2026, 14:44
Lukasz Kuzma: NOAC Monotherapy vs NOAC Plus Clopidogrel in AF Beyond One Year After DES
Lukasz Kuzma, Research Professor at University of Liverpool, shared a post on X about a recent article he and his colleague co-authored, adding:
“In our NEJM editorial with ESC Stroke Chair, we highlight the first RCT in AF more than 1 year after DES showing that NOAC monotherapy was not noninferior and statistically superior to NOAC plus clopidogrel for net adverse clinical events also with less bleeding.”
Title: Thromboprophylaxis for Atrial Fibrillation in Patients with Drug-Eluting Stents
Authors: Gregory Y.H. Lip and Lukasz Kuzma
Read the Full Article on The New England Journal of Medicine.
Stay updated with Hemostasis Today.
-
Sep 10, 2026, 05:12Douglas S. Campbell: Great to See a Strong Japanese Presence in 2026 Lasker Awards
-
Sep 10, 2026, 05:11Jan Hartmann: New Transformative Treatment for Hemophilia A
-
Sep 10, 2026, 05:09Shelby Bradford: Award-Winning Science Incoming
-
Sep 9, 2026, 17:57CRISPR/Cas Gene Editing in β-Thalassemia: From Molecular Correction to Clinical Reality
-
Sep 9, 2026, 17:38Cardiovascular Health in Bleeding Disorders – EHC
-
Sep 9, 2026, 17:33Manasvi Shah: Co-Inheritance of Alpha Globin Gene Multiplication With Beta Globin Gene Abnormalities
-
Sep 9, 2026, 17:29Christina Crossette-Thambiah: One of the Largest Studies to Date in Antiphospholipid Syndrome
-
Sep 9, 2026, 17:25Alan Nurden: A miR-146a Variant Reveals a New Pathway Linking Platelet Metabolism and Thrombosis
-
Sep 9, 2026, 17:17When Is Thrombophilia Testing Appropriate and How Can the Evidence Guide Clinical Care? – ISTH